Kezar Announces Topline Results from the PRESIDIO Trial of Zetomipzomib for the Treatment of Dermatomyositis and Polymyositis:
- Most patients saw clinically meaningful improvements in the primary endpoint measure of Total Improvement Score (TIS), but no differentiation from placebo was observed
- Zetomipzomib demonstrates a favorable safety and tolerability profile, including in the PRESIDIO Open-label Extension Study where weekly zetomipzomib has been administered for up to an additional 77 weeks
Kezar will learn more from this study with additional deeper analysis in the near future.
In addition, the PRESIDIO open-label extension study is providing data which will support the understanding of zetomipzomib in patients with DM and PM:
– self-administration of the drug was introduced during the open-label extension study, an important step in reducing burden to patients.
– high participation and persistence rate in the PRESIDIO open-label extension study is encouraging and the study remains active to current enrollees.
MSU values the relationship it has built over the past four years with Kezar. All along the way, Kezar has sought to be truly patient-centric. It is our hope that other opportunities will arise where we can collaborate to find novel treatments to ease the burden of myositis patients and caregivers.
PRESIDIO study (KZR-616-003; NCT04033926,EudraCT Number: 2019-002605-22)
PRESIDIO open-label extension study (KZR-616-003E; NCT04628936, EudraCT Number: 2020-004382-39)
Press Release: https://www.kezarlifesciences.com/investors/news-events/press-releases/detail/91/kezar-announces-topline-results-from-presidio-trial-of
Tags: clinical trials myositis research
